elbasvir grazoprevir zepatier
play

Elbasvir-Grazoprevir ( Zepatier ) Prepared by: H. Nina Kim, MD, MSc - PowerPoint PPT Presentation

Oct 10, 2022 •280 likes •1.44k views

Elbasvir-Grazoprevir ( Zepatier ) Prepared by: H. Nina Kim, MD, MSc David H. Spach, MD Last Updated: July 15, 2020 H EPATITIS C O NLINE www.hepatitisC.uw.edu E LBASVIR -G RAZOPREVIR ( Z EPATIER ) Background and Dosing Elbasvir-Grazoprevir (

  1. Elbasvir-Grazoprevir in Treatment-Naïve HCV GT 1, 4, or 6 C-EDGE TN: Baseline Characteristics Immediate Arm Delayed Arm All Patients Baseline Characteristic (n = 316) (n = 105) (n = 421) Age, mean 52 54 53 Male, % 54 53 54 Race, % Asian 17 12 16 Black 19 17 18 White 60 70 63 HCV genotype, n (%) 1a 157 (50) 54 (51) 211 (50) 1b 131 (42) 40 (38) 171 (41) 4 18 (6) 8 (8) 26 (6) 6 10 (3) 3 (3) 13 (3) HCV RNA >800,000 IU/ml, % 222 (70) 66 (63) 288 (68) IL28B non-CC, % 66 64 65 Fibrosis stage, % F0-2 67 66 66 F3 11 13 12 F4 22 21 22 Source: Zeuzem S, et al. Ann Intern Med. 2015;163:1-13.

  2. Elbasvir-Grazoprevir in Treatment-Naïve HCV GT 1, 4, or 6 C-EDGE TN: Results for Immediate Group C-EDGE TN: SVR12 Results by Genotype 100 100 99 Patients with SVR12 (%) 95 92 80 80 60 40 20 299/316 144/157 129/131 18/18 8/10 0 All GT 1a GT 1b GT 4 GT 6 Primary efficacy analysis included all patients who received ≥1 dose of drug. Source: Zeuzem S, et al. Ann Intern Med. 2015;163:1-13.

  3. Elbasvir-Grazoprevir in Treatment-Naïve HCV GT 1, 4, or 6 C-EDGE TN: Results for Immediate Group C-EDGE TN: SVR12 by Presence of Cirrhosis or High HCV RNA Level 100 100 97 94 92 80 Patients (%) with SVR 12 60 40 20 231/246 68/70 94/94 205/222 0 ≤800K IU/mL No Cirrhosis Cirrhosis >800K IU/mL Presence of Cirrhosis Baseline HCV RNA Source: Zeuzem S, et al. Ann Intern Med. 2015;163:1-13.

  4. Elbasvir-Grazoprevir in Treatment-Naïve HCV GT 1, 4, or 6 C-EDGE TN: Results Baseline NS5A Resistance-Associated Variants and SVR12 in GT1 Baseline NS5A RAVs* No Baseline NS5A RAVs 100 100 99 Patients (%) with SVR 12 94 80 60 58 40 20 11/19 133/135 17/18 112/112 0 Genotype 1a Genotype 1b * Patients with baseline GT1a RAVs with a ≤5 -fold shift to elbasvir: SVR12=90% (9 of 10) *Patients with baseline GT1a RAVs with a >5-fold shift to elbasvir: SVR12=22% (2 of 9) Source: Zeuzem S, et al. Ann Intern Med. 2015;163:1-13.

  5. Elbasvir-Grazoprevir in Treatment-Naïve HCV GT 1, 4, or 6 C-EDGE TN: Results Baseline NS3/4A Resistance-Associated Variants and SVR12 in GT1 Baseline NS3/4A RAVs No Baseline NS3/4A RAVs 100 100 97 96 Patients (%) with SVR 12 89 80 60 40 20 83/86 58/65 24/25 104/104 0 Genotype 1a Genotype 1b Source: Zeuzem S, et al. Ann Intern Med. 2015;163:1-13.

  6. Elbasvir-Grazoprevir in Treatment-Naïve HCV GT 1, 4 or 6 C-EDGE TN: Adverse Events Elbasvir-Grazoprevir Adverse Event (AE) Immediate Delayed (Placebo) (n = 316) (n = 105) Discontinuation due to AE 3 (0.9%) 1 (1%) Serious AEs 9 (3%) 3 (3%) 2 (0.6%) § Deaths 0 Any AE in ≥10% of patients Headache 52 (17%) 19 (18%) Fatigue 49 (16%) 18 (17%) Laboratory AEs ALT >5 x baseline 3 (0.9%) 0 AST >5 x baseline 1 (0.3%) 0 Total bilirubin elevation >5 x baseline 1 (0.3%) 0 Grade 3 or 4 hemoglobin 0 0 Grade 3 or 4 neutrophils 1 (0.3%) 1 (1%) Grade 3 or 4 creatinine 0 0 § Neither death was considered to be study-related. Source: Zeuzem S, et al. Ann Intern Med. 2015;163:1-13.

  7. Elbasvir-Grazoprevir in Treatment-Naïve HCV GT 1, 4, or 6 C-EDGE TN: Conclusions Conclusions : “ Grazoprevir-elbasvir achieved high SVR12 rates in treatment-naive cirrhotic and noncirrhotic patients with genotype 1, 4, or 6 infection. This once-daily, all-oral, fixed-combination regimen represents a potent new therapeutic option for chronic HCV infection.” Source: Zeuzem S, et al. Ann Intern Med. 2015;163:1-13.

  8. Phase 2 Treatment Naïve Elbasvir + Grazoprevir +/- Ribavirin in Treatment-Naïve HCV GT 2, 4, 5, or 6 C-SCAPE Source: Brown A, et al. J Viral Hepat. 2018;25:457-64.

  9. Elbasvir + Grazoprevir +/- RBV in Treatment-Naïve GT 2, 4, 5 or 6 C-SCAPE Study: Features C-SCAPE Trial  Design : Open-label, phase 2 trial to evaluate the efficacy and safety of elbasvir + grazoprevir + ribavirin versus elbasvir + grazoprevir versus grazoprevir + ribavirin in non-cirrhotic, treatment-naïve patients with GT 2, 4, 5, or 6 chronic hepatitis C infection  Entry Criteria - Chronic HCV GT2 (n = 60), GT4 (n = 20), GT5 (n = 8), or GT6 (n = 10) - Age 18 years or older - No prior HCV treatment - HCV RNA ≥10,000 IU/mL - No evidence of cirrhosis  Primary End-Point : SVR12 Source: Brown A, et al. J Viral Hepat. 2018;25:457-64.

  10. Elbasvir + Grazoprevir +/- RBV in Treatment-Naïve GT 2, 4, 5 or 6 C-SCAPE Study: Study Design for GT 1 Week 0 12 24 n = 30 EBR-GZR + RBV SVR12 GT 2 Non-cirrhotic GZR + RBV SVR12 n = 30 n = 19 EBR-GZR + RBV SVR12 GT 4, 5, or 6 Non-cirrhotic n = 19 EBR-GZR SVR12 Abbreviations : EBR = Elbasvir; GZR = Grazoprevir; RBV = ribavirin Drug Dosing Elbasvir (50 mg) once daily Grazoprevir (100 mg) once daily Ribavirin (weight-based and divided bid): 800 to 1400 mg/day Source: Brown A, et al. J Viral Hepat. 2018;25:457-64.

  11. Elbasvir + Grazoprevir +/- RBV in Treatment-Naïve GT 2, 4, 5 or 6 C-SCAPE Study: Baseline Characteristics Genotype 2 Genotype 4, 5, 6 Baseline EBR + GZR + RBV GZR + RBV EBR + GZR + RBV EBR-GZR Characteristic (n = 30) (n = 30) (n = 19) (n = 19) Mean age, y (range) 47.3 48.3 52.2 52.8 Male sex, % 63.3 56.7 42.1 63.2 Race, % White 100 86.7 73.7 68.4 Other 0 13.3 26.3 31.6 HCV Genotype, n 2 30 26 0 0 4 0 0 10 10 5 0 0 4 4 6 0 0 4 4 1 -- 4 -- -- HCV RNA ≤ 2 million 36.7 36.7 57.9 36.8 >2 million 63.3 63.3 42.1 63.2 *Excluded from modified intent-to-treat analysis due to discordant genotype Source: Brown A, et al. J Viral Hepat. 2018;25:457-64.

  12. Elbasvir + Grazoprevir +/- RBV in Treatment-Naïve GT 2, 4, 5, or 6 C-SCAPE Study: Results C-SCAPE: SVR12 by Genotype and Regimen EBR + GZR + RBV x 12 weeks EBR + GZR + RBV x 12 weeks GZR + RBV x 12 weeks EBR + GZR x 12 weeks 100 100 100 Patients (%) with SVR 12 90 80 80 75 75 73 60 40 20 25 24/30 19/26 10/10 9/10 4/4 1/4 3/4 3/4 0 GT2 GT4 GT5 GT6 Source: Brown A, et al. J Viral Hepat. 2018;25:457-64.

  13. Elbasvir + Grazoprevir +/- RBV in Treatment-Naïve GT 2, 4, 5 or 6 C-SCAPE Study: Conclusions Conclusions : “The se data support the inclusion of participants with genotype 4 or 6 infection in the elbasvir-grazoprevir phase 3 studies. Elbasvir-grazoprevir ± ribavirin was unsatisfactory for participants with genotype 2 or 5 infection. ” Source: Brown A, et al. J Viral Hepat. 2018;25:457-64.

  14. Elbasvir-Grazoprevir in Treatment-Experienced Patients

  15. Phase 3 Treatment Experienced Elbasvir-Grazoprevir +/- Ribavirin in HCV Genotype 1, 4 or 6 C-EDGE Treatment Experienced (TE) Source: Kwo P, et al. Gastroenterology. 2017;152:164-75.

  16. Elbasvir-Grazoprevir +/- Ribavirin in HCV Genotype 1, 4 or 6 C-EDGE TE Study: Features C-EDGE TE Trial  Design : Randomized, open label, parallel-group, phase 3 trial examining the safety and efficacy of a fixed-dose combination of elbasvir-grazoprevir with or without ribavirin for 12 or 16 weeks in treatment-experienced adults with GT 1, 4, or 6 HCV and previous failure of peginterferon plus ribavirin  Entry Criteria - Chronic HCV Genotype 1, 4 or 6 - 18 years or older - HCV RNA ≥10,000 IU/mL - History of peginterferon plus ribavirin treatment failure - Patients with compensated cirrhosis accepted - Some patients with HIV infection accepted  Primary End-Point : SVR12 Source: Kwo P, et al. Gastroenterology. 2017;152:164-75.

  17. Elbasvir-Grazoprevir +/- Ribavirin in HCV Genotype 1, 4 or 6 C-EDGE TE: Study Design Week 0 12 16 24 28 36 EBR-GRZ n = 105 SVR12 SVR12 n = 104 EBR-GRZ + RBV GT 1, 4 or 6 Prior Treatment (n = 420) n = 105 EBR-GRZ SVR12 n = 106 EBR-GRZ + RBV SVR12 Abbreviations : EBR-GZR = elbasvir-grazoprevir; RBV = ribavirin N =14 Drug Dosing Elbasvir-grazoprevir (50/100 mg): fixed dose combination; one pill once daily Ribavirin (weight-based and divided bid): 800 to 1400 mg/day Source: Kwo P, et al. Gastroenterology. 2017;152:164-75.

  18. Elbasvir-Grazoprevir +/- Ribavirin in HCV Genotype 1, 4 or 6 C-EDGE TE : Baseline Characteristics 12-Week Treatment 16-Week Treatment Baseline EBR-GRZ EBR-GRZ + RBV EBR-GRZ EBR-GRZ + RBV Characteristic (n = 105) (n = 104) (n = 105) (n = 106) 56 (25 – 76) 56 (23 – 75) 55 (31 – 73) 55 (19 – 77) Age, yrs median (range) Male sex, % 63 69 66 60 Race, n (%) Caucasian 66 (63) 70 (67) 72 (69) 78 (74) African American 23 (22) 24 (23) 9 (9) 15 (14) Asian 15 (14) 9 (9) 22 (21) 10 (9) HCV Genotype, % 1a 61 (58) 60 (58) 48 (46) 58 (55) 1b 34 (32) 29 (28) 48 (46) 36 (34) 4 9 (9) 15 (14) 5 (5) 8 (8) 6 0 (0) 0 (0) 4 (4) 2 (2) Cirrhosis, % 37 (35) 35 (34) 38 (36) 37 (35) HIV coinfection, % 6 (6) 5 (5) 6 (6) 4 (4) Prior treatment response Relapse, % 35 (33) 38 (37) 38 (36) 40 (38) Partial response, % 21 (20) 22 (21) 21 (20) 23 (22) Prior null, % 49 (47) 44 (42) 46 (44) 43 (41) Source: Kwo P, et al. Gastroenterology. 2017;152:164-75.

  19. Elbasvir-Grazoprevir +/- Ribavirin in HCV Genotype 1, 4 or 6 C-EDGE TE : Results C-EDGE TE: SVR 12*, by Genotype 100 100 96 Patients with SVR 12 (%) 89 80 60 40 20 356/370 32/36 4/4 0 Genotype 1 Genotype 4 Genotype 6 * Analysis per protocol: excluding patients who dropped out due to reasons other than virologic failure Source: Kwo P, et al. Gastroenterology. 2017;152:164-75.

  20. Elbasvir-Grazoprevir +/- Ribavirin in HCV Genotype 1, 4 or 6 C-EDGE TE : Results C-EDGE TE: SVR 12* by Regimen and Treatment Duration (GT 1, 4, or 6) 100 98 Patients with SVR 12 (%) 94 92 92 80 60 40 20 97/105 98/104 97/105 104/106 0 EBR-GRZ EBR-GRZ + RBV EBR-GRZ EBR-GRZ + RBV 12-Week Regimen 16-Week Regimen * Analysis per intent to treat Source: Kwo P, et al. Gastroenterology. 2017;152:164-75.

  21. Elbasvir-Grazoprevir +/- Ribavirin in HCV Genotype 1, 4 or 6 C-EDGE TE : Results C-EDGE TE: SVR 12 by Regimen, Treatment Duration, and GT1 Subtype Genotype 1a Genotype 1b 100 100 100 100 97.9 Patients with SVR 12 (%) 96.6 93.8 93.3 91.7 80 60 40 20 55/60 34/34 56/60 28/29 45/48 46/47 55/55 37/37 0 EBR-GRZ EBR-GRZ + RBV EBR-GRZ EBR-GRZ + RBV 12-Week Regimen 16-Week Regimen Source: Kwo P, et al. Gastroenterology. 2017;152:164-75.

  22. Elbasvir-Grazoprevir +/- Ribavirin in HCV Genotype 1, 4 or 6 C-EDGE TE : Results C-EDGE TE: SVR 12 in Patients with Baseline NS5A RAVs Genotype 1a Genotype 1b 100 100 100 100 Patients with SVR 12 (%) 91.7 80 80.0 66.7 60 60.0 50.0 40 20 6/10 4/4 6/9 4/5 3/6 11/12 6/6 9/9 0 EBR-GRZ EBR-GRZ + RBV EBR-GRZ EBR-GRZ + RBV 12-Week Regimen 16-Week Regimen Source: Kwo P, et al. Gastroenterology. 2017;152:164-75.

  23. Elbasvir-Grazoprevir +/- Ribavirin in HCV Genotype 1, 4 or 6 C-EDGE TE : Results Conclusions : “The combination tablet of elbasvir and grazoprevir, with or without ribavirin, was highly efficacious in inducing an SVR12 in patients with HCV genotype 1, 4, or 6 infection failed by previous treatment with peg-interferon and ribavirin, including patients with cirrhosis and/or a prior null response. The treatment was generally well tolerated. ” Source: Kwo P, et al. Gastroenterology. 2017;152:164-75.

  24. Phase 2 Treatment Experienced Elbasvir + Grazoprevir + Ribavirin in PI-experienced HCV GT1 C-SALVAGE Source: (1) Buti M, et al. Clin Infect Dis. 2016;62:32-6. (2) Forns X, et al. J Hepatol. 2015;63:564-72.

  25. Elbasvir + Grazoprevir + Ribavirin in PI-experienced HCV GT1 C-SALVAGE Study: Features C-SALVAGE Trial  Design : Prospective, open-label, single-arm, phase 2 trial of elbasvir plus grazoprevir plus ribavirin for 12 weeks in treatment-experienced patients with HCV GT1, with or without cirrhosis, and previous failure of peginterferon and ribavirin plus an early-generation HCV protease inhibitor (boceprevir, simeprevir, or telaprevir)  Entry Criteria - Chronic HCV genotype 1 - Age 18 years or older - HCV RNA ≥10,000 IU/mL - Prior treatment failure with ≥4 weeks of peginterferon + ribavirin + PI - Patients with compensated cirrhosis accepted  Primary End-Points : SVR12 data analysis: Buti M, et al. Clin Infect Dis. 2016;62:32-6. SVR24 data analysis: Forns X, et al. J Hepatol. 2015;63:564-72. Source: (1) Buti M, et al. Clin Infect Dis. 2016;62:32-6. (2) Forns X, et al. J Hepatol. 2015;63:564-72.

  26. Elbasvir + Grazoprevir + Ribavirin in PI-experienced HCV GT1 C-SALVAGE Study: Design Week 0 12 24 PI+PR experienced Genotype 1 N=79 SVR12 EBR + GZR + RBV Non-cirrhotic (N=45) Cirrhotic (N=34) Abbreviations : EBR = elbasvir; GZR = grazoprevir; RBV = ribavirin; PI = protease inhibitor; PR = peginterferon+ribavirin Drug Dosing : Elbasvir: 50 mg once daily Grazoprevir: 100 mg once daily Ribavirin (weight-based and divided bid): 800 to 1400 mg/day Source: Buti M, et al. Clin Infect Dis. 2016;62:32-6.

  27. Elbasvir + Grazoprevir + Ribavirin in PI-experienced HCV GT1 C-SALVAGE Study: Participants Baseline All Patients Baseline NS3 RAVs* No Baseline NS3 RAVs* Characteristic (n = 79) (n = 34) (n = 44) Mean age, years 54.4 53.9 54.6 Male/Female, % 58.2/41.8 61.8/38.2 54.5/45.5 HCV genotype, % 1a 38.0 67.6 15.9 1b 62.0 32.4 84.1 Cirrhosis, % 43.0 44.1 43.2 Previous PI, % Boceprevir 35.4 29.4 38.6 Telaprevir 54.4 55.9 54.5 Simeprevir 10.1 14.7 6.8 Non-virologic failure + , % 16.5 5.9 25.0 * Among evaluable patients + Reasons for the 13 non-virologic failure included adverse events/drug intolerance (n=12) and short course regimen in a clinical trial (n=1) Source: Forns X, et al. J Hepatol. 2015;63:564-72.

  28. Elbasvir + Grazoprevir + Ribavirin in PI-experienced HCV GT1 C-SALVAGE Study: Results C-SALVAGE: SVR 24* by Baseline Factors 100 96.2 95.5 94.1 91.7 80 Patients (%) with SVR24 60 40 20 76/79 63/66 33/36 32/34 0 All patients Prior virologic failure NS3 +/- NS5 RAVs Cirrhosis * Analysis per intent to treat Source: Buti M, et al. Clin Infect Dis. 2016;62:32-6.

  29. Elbasvir + Grazoprevir + Ribavirin in PI-experienced HCV GT1 C-SALVAGE Study: Results SVR24 Related to Baseline RAVs in 79 Patients with Prior Virologic Failure SVR24 in Patients with Categories of RAVs Baseline RAV Baseline RAVs NS3 RAV 34/79 (43%) 31/34 (91%) NS5A RAV 9/79 (11%) 8/9 (89%) Total 43/79 (54%) 39/43 (91%) RAV = Resistance Associated Variants Source: Buti M, et al. Clin Infect Dis. 2016;62:32-6.

  30. Elbasvir + Grazoprevir + Ribavirin in PI-experienced HCV GT1 C-SALVAGE Study: Adverse Events Grazoprevir + Elbasvir + Ribavirin Adverse Event (AE), n (%) (n = 79) Discontinuation due to AE 1 (1.3%) Serious AEs 4 (5.1%) Deaths 0 Specific AE in ≥10% of patients Fatigue 22 (28%) Headache 15 (19%) Asthenia 12 (15%) Nausea 9 (12%) Grade 3 or 4 laboratory abnormality Grade 3 Grade 4 Total bilirubin 4 (5.1%) 1 (1.3%) Direct bilirubin 2 (2.5%) 0 AST or ALT 0 0 Lipase 4 (5.1%) 0 Hemoglobin 2 (2.5%) 0 Source: Forns X, et al. J Hepatol. 2015;63:564-72.

  31. Elbasvir + Grazoprevir + Ribavirin in PI-experienced HCV GT1 C-SALVAGE Study: Conclusions Conclusions : “ Grazoprevir and elbasvir with ribavirin for 12 weeks maintained HCV suppression for at least 24 weeks posttherapy without late relapses. Baseline resistance-associated variants (RAVs) stably reappeared at relapse in all 3 patients with virologic failure. NS5A RAVs emerging at relapse persisted for the full 24-week follow-up period. If confirmed, this finding could complicate retreatment of the small number of patients failing regimens containing an NS5A inhibitor. ” Source: Buti M, et al. Clin Infect Dis. 2016;62:32-6.

  32. Phase 2 Treatment Naïve and Treatment Experienced Elbasvir-Grazoprevir + Sofosbuvir +/- RBV in GT 3 C-ISLE Source: Foster GR, et al. Hepatology. 2018;67:2113-26.

  33. Elbasvir + Grazoprevir +/- Ribavirin in HCV GT3 C-ISLE Study: Features C-ISLE Trial  Design : Randomized, open label, phase 2 trial examining the safety and efficacy of elbasvir-grazoprevir plus sofosbuvir, with or without ribavirin, for 8 or 12 weeks in treatment-naïve adults with HCV GT3 and compensated cirrhosis, or for 12 or 16 weeks in adults with HCV GT3 and prior with treatment failure with peginterferon plus ribavirin (PR)  Entry Criteria - Chronic HCV genotype 3 - 18 years or older - Compensated cirrhosis (Child-Pugh class A) and HIV allowed - Exclusions: prior DAA therapy, HBV, Child-Pugh class B or C cirrhosis  Primary End-Point : SVR12 Source: Foster GR, et al. Hepatology. 2018;67:2113-26.

  34. Elbasvir-Grazoprevir + Sofosbuvir +/- RBV in HCV GT3 Cirrhosis C-ISLE Study: Study Design Week 0 8 12 16 EBR-GZR + // SVR24 n = 23 SOF + RBV Treatment- Naive // EBR-GZR + SOF n = 24 SVR24 n = 17 EBR-GZR + SOF // SVR24 Treatment- n = 18 EBR-GZR + SOF + RBV // SVR24 Experienced n = 18 EBR-GZR + SOF // SVR24 Abbreviations : EBR = elbasvir; GRZ = grazoprevir; SOF = sofosbuvir; RBV = ribavirin Drug Dosing Elbasvir: 50 mg once daily, Grazoprevir: 100 mg once daily, Sofosbuvir: 400 mg once daily Ribavirin (weight-based and divided bid): 800 to 1400 mg/day Source: Foster G, et al. Hepatology 2018;67:2113-6.

  35. Elbasvir-Grazoprevir + Sofosbuvir +/- Ribavirin in HCV GT3 C-ISLE: Study Design Week 0 8 12 16 24 28 HCV GT3: Treatment-Naïve Participants EBR-GZR + SOF + RBV SVR12 n = 23 EBR-GZR + SOF n = 24 SVR12 HCV GT3: Peginterferon + Ribavirin Treatment Experienced Participants n = 17 EBR-GZR + SOF SVR12 n = 18 EBR-GZR + SOF + RBV SVR12 EBR-GZR + SOF n = 18 SVR12 Abbreviations : EBR-GZR = elbasvir-grazoprevir; RBV = ribavirin: SOF = sofosbuvir Drug Dosing Elbasvir: 50 mg once daily; Grazoprevir: 100 mg once daily; Sofosbuvir: 400 mg once daily Ribavirin (weight-based and divided bid): 800 to 1400 mg/day Source: Foster GR, et al. Hepatology. 2018;67:2113-26.

  36. Elbasvir-Grazoprevir + Sofosbuvir +/- Ribavirin in HCV GT3 C-ISLE Study: Baseline Characteristics Treatment-Naïve Treatment-Experienced Baseline EBR-GZR + EBR-GZR EBR-GZR EBR-GZR + EBR-GZR + SOF Characteristic SOF + RBV + SOF + SOF SOF + RBV 16 weeks 8 weeks 12 weeks 12 weeks 12 weeks (n = 18) (n = 23 (n = 24) (n = 17) (n = 18) Median age, y (range) 51 (37-68) 48 (32-64) 58 (48-68) 56 (38-70) 53 (43-66) Male, % 56.5 70.8 64.7 66.7 83.3 Female, % 43.5 29.2 35.3 33.3 16.7 Race White, % 69.6 79.2 76.5 50.0 66.7 Asian, % 26.1 16.7 23.5 50.0 33.3 BMI, % <30 kg/m 2 73.9 75.0 76.5 72.2 61.1 ≥30 kg/m 2 26.1 25.0 23.5 27.8 38.9 Baseline HCV RNA ≤ 2 million IU/mL, % 52.2 41.7 58.8 44.4 61.1 >2 million IU/mL, % 47.8 58.3 41.2 55.6 38.9 Source: Foster GR, et al. Hepatology. 2018;67:2113-26.

  37. Elbasvir-Grazoprevir + Sofosbuvir +/- Ribavirin in HCV GT3 C-ISLE Study: Results 100 100 96 94 94 Patients with SVR 12 (%) 91 80 60 40 20 21/23 23/24 17/17 17/18 17/18 0 EBR-GZR + SOF + EBR-GZR + SOF + EBR-GZR + SOF x EBR-GZR + SOF + EBR-GZR + SOF x RBV x 8 Weeks RBV x 12 Weeks 12 weeks RBV x 12 weeks 16 weeks Treatment-Naive Treatment-Experienced Abbreviations: EBR-GZR = elbasvir-grazoprevir; SOF = sofosbuvir; RBV = ribavirin Source: Foster GR, et al. Hepatology. 2018;67:2113-26.

  38. Elbasvir-Grazoprevir + Sofosbuvir +/- Ribavirin in HCV GT3 C-ISLE Study: Results 100 100 96 94 94 Patients with SVR 12 (%) 91 80 60 40 1 DC due 1 withdrew 2 relapses 1 LTFU to AE consent 20 21/23 23/24 17/17 17/18 17/18 0 EBR-GZR + SOF + EBR-GZR + SOF + EBR-GZR + SOF x EBR-GZR + SOF + EBR-GZR + SOF x RBV x 8 Weeks RBV x 12 Weeks 12 weeks RBV x 12 weeks 16 weeks Treatment-Naive Treatment-Experienced Abbreviations: EBR-GZR = elbasvir-grazoprevir; SOF = sofosbuvir; RBV = ribavirin Source: Foster GR, et al. Hepatology. 2018;67:2113-26.

  39. Elbasvir-Grazoprevir + Sofosbuvir +/- RBV in HCV GT3 Cirrhosis C-ISLE Study: Results by Presence of RAS C-ISLE: SVR12 Rates by Presence of RAS RAS No RAS 100 100 98 98 Patients (%) with SVR 12 97 80 60 40 20 85/87 3/3 49/50 46/47 0 NS3 NS5A RAS = resistance-associated substitution. 97 patients contributed to RAS analysis. Of these, 90 had sequences available for NS3 analysis and all 97 for NS5A analysis. Source: Foster G, et al. Hepatology 2018;67:2113-6.

  40. Elbasvir-Grazoprevir + Sofosbuvir +/- RBV in HCV GT3 Cirrhosis C-ISLE Study: Adverse Events Treatment-naïve Treatment-Experienced Adverse Event (AE), EBR-GZR + EBR-GZR + EBR-GZR + EBR-GZR + EBR-GZR + SOF + RBV SOF SOF + RBV SOF SOF n (%) 8 weeks 12 weeks 12 weeks 12 weeks 16 weeks (n = 23) (n = 24) (n = 17) (n = 18) (n = 18) Drug-related AE 14 (61) 13 (54) 5 (29) 15 (83) 11 (61) Any AE 20 (87) 21 (88) 14 (82) 17 (94) 17 (94) Fatigue 6 (26) 8 (33) 6 (35) 10 (56) 6 (33) Nausea 4 (17) 3 (13) 3 (18) 6 (33) 3 (17) Headache 5 (22) 7 (29) 5 (29) 11 (61) 7 (39) Rash 3 (13) 1 (4) 1 (6) 3 (17) 1 (6) Serious AE 0 0 1 (6) 3 (17) 1 (6) Discontinuation due to AE 0 0 0 0 1 (6) Deaths 0 0 0 0 0 Hemoglobin <10 mg/dL 0 0 1 (6) 2 (11) 0 Bilirubin <5x baseline 0 0 0 0 0 ALT/AST >5x baseline 0 0 0 0 0 Source: Foster G, et al. Hepatology 2018;67:2113-6.

  41. Elbasvir-Grazoprevir + Sofosbuvir +/- Ribavirin in HCV GT3 C-ISLE Study: Conclusions Conclusion : “ Data from this study support the use of elbasvir-grazoprevir plus sofosbuvir for 12 weeks without reibavirin for treatment-naive and peginterferon/ribavirin- experienced people with GT3 infection and cirrhosis. ” Source: Foster GR, et al. Hepatology. 2018;67:2113-26.

  42. Phase 2 Treatment Naïve and Treatment Experienced Elbasvir-Grazoprevir + Sofosbuvir +/- RBV in GT 3 Patients with Compensated Cirrhosis C-ISLE Source: Foster G, et al. Hepatology 2018;67:2113-6.

  43. Elbasvir-Grazoprevir + Sofosbuvir +/- RBV in HCV GT3 Cirrhosis C-ISLE Study: Baseline Characteristics Treatment-naïve Treatment-Experienced Baseline EBR-GZR + EBR-GZR + EBR-GZR + EBR-GZR + EBR-GZR + SOF + RBV SOF SOF + RBV SOF SOF Characteristic 8 wks 12 wks 12 wks 12 wks 16 wks (n = 23) (n = 24) (n = 17) (n = 18 n = 18) Median age, yrs (range) 51 (37-68) 48 (32-64) 58 (48-68) 56 (38-70) 53 (43-66) Male, % 56.5 70.8 64.7 66.7 83.3 Race White 69.6 79.2 76.5 50 66.7 Asian 26.1 16.7 23.5 50 33.3 Other 4.3 4.2 0 0 0 BMI ≥30 kg/m 2 , % 26.1 25 23,5 27.8 38.9 Prior PR history, % Intolerant 0 0 5.6 n/a n/a Null responder 0 5.6 0 Relapser 100 94.4 94.4 IL28B non-CC, % 39.1 33.3 64.7 61.1 61.1 HCV RNA >2 million 47.8 58.3 41.2 55.6 38.9 IU/mL, % Source: Foster G, et al. Hepatology 2018;67:2113-6.

  44. Elbasvir-Grazoprevir + Sofosbuvir +/- RBV in HCV GT3 Cirrhosis C-ISLE Study: Conclusions Conclusion : “ In conclusion, high efficacy was demonstrated in treatment-naive and peginterferon/ribavirin treatment – experienced participants with HCV GT3 infection and cirrhosis, with SVR12 rates of 100% achieved in participants receiving elbasvir-grazoprevir plus sofosbuvir with or without ribavirin for 12 weeks. ” Source: Foster G, et al. Hepatology 2018;67:2113-6.

  45. Phase 2b Treatment Naïve and Treatment Experienced Elbasvir + Grazoprevir +/- RBV in GT 1 Cirrhotics & Null Responders C-WORTHY Source: Lawitz E, et al. Lancet 2015;385:1075-86.

  46. Elbasvir + Grazoprevir +/- Ribavirin in HCV GT1 C-WORTHY Study: Features C-WORTHY (Protocol 035) Trial  Design : Randomized, open label phase 2 trial examining the safety and efficacy of elbasvir plus grazoprevir, with or without ribavirin, for 12 or 18 weeks in treatment-naïve patients with cirrhosis (cohort 1) or patients with a previous null response to peginterferon/ribavirin (PR) (cohort 2)  Entry Criteria - Chronic HCV Genotype 1 - Age 18 years or older - HCV RNA ≥10,000 IU/mL - ALT and AST <350 IU/L - Cohort 1: compensated cirrhosis (Child-Pugh class A) - Cohort 2: prior PR null response (<2 log 10 HCV RNA decline at week 12)  Primary End-Point : SVR12 Source: Lawitz E, et al. Lancet 2015;385:1075-86.

  47. Elbasvir + Grazoprevir +/- Ribavirin in HCV GT1 C-WORTHY: Study Design Cohort 1 (Cirrhosis) Week 0 12 18 24 30 EBR + GZR + RBV SVR12 n = 31 Cohort 1 EBR + GZR n = 29 SVR12 Treatment-Naive Cirrhosis n = 32 EBR + GZR + RBV SVR12 (n = 123) n = 31 EBR + GZR SVR12 Abbreviations : EBR = elbasvir; GZR = grazoprevir; RBV = ribavirin Drug Dosing Elbasvir: 50 mg once daily Grazoprevir: 100 mg once daily Ribavirin (weight-based and divided bid): 800 to 1400 mg/day Source: Lawitz E, et al. Lancet 2015;385:1075-86.

  48. Elbasvir + Grazoprevir +/- Ribavirin in HCV GT1 C-WORTHY: Study Design Cohort 2 (Null Responders) Week 0 12 18 24 30 EBR + GZR + RBV SVR12 n = 32 n = 33 EBR + GZR SVR12 Cohort 2 Null Responders (n = 130) n = 33 EBR + GZR + RBV SVR12 n = 32 EBR + GZR SVR12 Abbreviations : EBR = elbasvir; GZR = grazoprevir; RBV = ribavirin Drug Dosing Elbasvir: 50 mg once daily Grazoprevir: 100 mg once daily Ribavirin (weight-based and divided bid): 800 to 1400 mg/day Source: Lawitz E, et al. Lancet 2015;385:1075-86.

  49. Elbasvir + Grazoprevir +/- Ribavirin in HCV GT1 C-WORTHY: Baseline Characteristics Treatment-naïve + cirrhosis Null responders Baseline EBR + GZR + RBV EBR + GZR EBR + GZR + RBV EBR + GZR Characteristic (n = 63) (n = 60) (n = 65) (n = 65) Mean age, y (range) 58 (41-79) 59 (42-82) 54 (24-76) 54 (18-77) Male, % 54 67 55 58 Race White 90 92 92 94 Non-white 10 8 8 6 Hispanic/Latino, % 11 7 0 2 HCV Genotype, % 1a 70 72 57 60 1b 29 25 43 40 Unclassified 2 3 0 0 IL28B CC, % 27 35 0 3 Cirrhosis, % 100 98 35 38 HCV RNA >2 million 65 73 78 86 IU/mL, % Source: Lawitz E, et al. Lancet 2015;385:1075-86.

  50. Elbasvir + Grazoprevir +/- Ribavirin in HCV GT1 C-WORTHY : Results for Naïve Cirrhotics (Cohort 1) C-WORTHY: SVR 12* by Treatment Duration and Regimen 100 97 97 94 Patients with SVR 12 (%) 90 80 60 40 20 28/31 28/29 31/32 29/31 0 EBR + GZR + RBV EBR + GZR EBR + GZR + RBV EBR + GZR 12-Week Regimen 18-Week Regimen Abbreviations: EBR = elbasvir; GZR = grazoprevir; RBV = ribavirin *Analysis per intent to treat Source: Lawitz E, et al. Lancet 2015;385:1075-86.

  51. Elbasvir + Grazoprevir +/- Ribavirin in HCV GT1 C-WORTHY : Results for Null Responders (Cohort 2) C-WORTHY: SVR 12* by Treatment Duration and Regimen 100 100 97 94 Patients with SVR 12 (%) 91 80 60 40 20 30/32 30/33 33/33 31/32 0 EBR + GZR + RBV EBR + GZR EBR + GZR + RBV EBR + GZR 12-Week Regimen 18-Week Regimen Abbreviations: EBR = elbasvir; GZR = grazoprevir; RBV = ribavirin *Analysis per intent to treat Source: Lawitz E, et al. Lancet 2015;385:1075-86.

  52. Elbasvir + Grazoprevir +/- Ribavirin in HCV GT1 C-WORTHY: Adverse Events Treatment-naïve with cirrhosis Null Responders Adverse event (AE), % EBR + GZR + RBV EBR + GZR EBR + GZR + RBV EBR + GZR (n = 63) (n = 60) (n = 65) (n = 65) Serious AE 2 3 3 3 Discontinuation due to AE 2 0 2 0 Death 0 0 2 0 AEs in ≥10% of patients Fatigue 22 23 23 35 Headache 11 35 23 23 Asthenia 5 12 18 20 Laboratory events Hemoglobin <10 g/dL 13 0 6 0 Hemoglobin <8.5 g/dL 2 0 0 0 Total bilirubin >5 x baseline 3 0 2 0 ALT or AST >2 to ≤5 x ULN* 0 3 0 5 ALT or AST >5 x ULN* 0 0 2 0 *ULN = upper limit of normal Source: Lawitz E, et al. Lancet 2015;385:1075-86.

  53. Elbasvir + Grazoprevir +/- Ribavirin in HCV GT1 C-WORTHY Study: Conclusions Interpretation : “ Treatment with grazoprevir plus elbasvir, both with and without ribavirin and for both 12 and 18 weeks' treatment duration, showed high rates of efficacy in previously untreated patients with cirrhosis and previous PR-null responders with and without cirrhosis. These results support the phase 3 development of grazoprevir plus elbasvir. ” Source: Lawitz E, et al. Lancet 2015;385:1075-86.

  54. Elbasvir-Grazoprevir in HIV Coinfection

  55. Phase 3 Treatment Naïve HIV Coinfection Elbasvir-Grazoprevir in HCV and HIV Coinfection, GT 1, 4 or 6 C-EDGE CO-INFECTION Source: Rockstroh JK, et al. Lancet HIV. 2015;2:e319-27.

  56. Elbasvir-Grazoprevir in HCV-HIV Coinfection GT 1, 4 or 6 C-EDGE CO-INFECTION: Study Features C-EDGE Trial  Design : Prospective, open-label, single-arm study examining the safety and efficacy of a fixed-dose combination of elbasvir-grazoprevir for 12 weeks in treatment-naïve patients with chronic HCV genotype 1, 4, or 6 and HIV coinfection.  Entry Criteria - Chronic HCV Genotype 1, 4, or 6 - Age 18 years or older - HCV RNA ≥10,000 IU/mL - No prior treatment - Compensated cirrhosis permitted - HIV infection  Primary End-Point : SVR12 Source: Rockstroh JK, et al. Lancet HIV. 2015;2:e319-27.

  57. Elbasvir-Grazoprevir in HCV-HIV Coinfection GT 1, 4 or 6 C-EDGE CO-INFECTION: Study Design Week 0 12 24 HIV-HCV Coinfected Treatment-naïve Elbasvir-Grazoprevir n = 218 SVR12 GT 1, 4, or 6 Drug Dosing Elbasvir-grazoprevir (50/100 mg): fixed dose combination; one pill once daily Source: Rockstroh JK, et al. Lancet HIV. 2015;2:e319-27.

  58. Elbasvir-Grazoprevir in HCV-HIV Coinfection GT 1, 4 or 6 C-EDGE CO-INFECTION: Participants Baseline Characteristic Elbasvir-Grazoprevir (n = 218) Age, mean 49 Male, n (%) 183 (84%) Race, n (%) White 167 (77%) Black or African-American 38 (17%) Other 13 (6%) HCV genotype, n (%) 1a 144 (66%) 1b 44 (20%) 4 28 (13%) 6 2 (1%) Fibrosis stage, n (%) F0-2 160 (73%) F3 23 (11%) F4 35 (16%) Mean baseline HCV RNA, log 10 IU/ml 6.03 Source: Rockstroh JK, et al. Lancet HIV. 2015;2:e319-27.

  59. Elbasvir-Grazoprevir in HCV-HIV Coinfection GT 1, 4 or 6 C-EDGE CO-INFECTION: Participants HIV Characteristics Elbasvir-Grazoprevir (n = 218) Median CD4 cell count, (IQR) 568 (424-766) ART Status On ART with undetectable HIV RNA 211 (97%) ART naïve 7 (3%) ART nucleos(t)ide pair Abacavir-containing 47 (22%) Tenofovir-containing 164 (75%) None 7 (3%) ART Third Agent Raltegravir 113 (52%) Dolutegravir 59 (27%) Rilpivirine 38 (17%) None 8 (4%) IQR = interquartile range; ART = antiretroviral therapy Source: Rockstroh JK, et al. Lancet HIV. 2015;2:e319-27.

  60. Elbasvir-Grazoprevir in HCV-HIV Coinfection GT 1, 4 or 6 C-EDGE CO-INFECTION: Results C-EDGE CO-INFECTION: SVR12 Results by Genotype 100 96 97 96 96 Patients with SVR12 (%) 80 60 40 20 210/218 139/144 42/44 27/28 0 All GT1a GT1b GT4 Genotype Overall SVR12 results includes the 2 patients with GT 6, who both achieved SVR12. Source: Rockstroh JK, et al. Lancet HIV. 2015;2:e319-27.

  61. Elbasvir-Grazoprevir in HCV-HIV Coinfection GT 1, 4 or 6 C-EDGE CO-INFECTION: Adverse Events Adverse Event (AE), n (%) Elbasvir-Grazoprevir (n = 218) Discontinuation due to AE 0 Serious AEs 2 (1%) Deaths 0 Any AE in >5% of patients Fatigue 29 (13%) Headache 27 (12%) Nausea 20 (9%) Upper respiratory tract infection 18 (8%) Diarrhea 16 (7%) Insomnia 15 (7%) Grade 3 or 4 laboratory abnormality Grade 3 Grade 4 Total bilirubin 1 (<1%) 0 ALT elevation 3 (1%) 2 (1%) AST elevation 0 1 (<1%) Hemoglobin 0 0 Source: Rockstroh JK, et al. Lancet HIV. 2015;2:e319-27.

  62. Elbasvir-Grazoprevir in HCV-HIV Coinfection GT 1, 4 or 6 C-EDGE CO-INFECTION: Conclusions Conclusions : “ This HCV treatment regimen seems to be effective and well tolerated for patients co-infected with HIV with or without cirrhosis. These data are consistent with previous trials of this regimen in the monoinfected population. This regimen continues to be studied in phase 3 trials. ” Source: Rockstroh JK, et al. Lancet HIV. 2015;2:e319-27.

  63. Phase 2 Treatment Naïve HIV Coinfection Elbasvir + Grazoprevir +/- RBV: HCV GT1 +/- HIV Coinfection C-WORTHY Coinfection Source: Sulkowski M, et al. Lancet. 2015;385:1087-97.

  64. Elbasvir + Grazoprevir +/- RBV in HCV GT1 +/- HIV Coinfection C-WORTHY Coinfection: Study Features C-WORTHY (Protocol 035) Trial  Design : Randomized, open-label phase 2 trial examining the safety and efficacy of a fixed-dose combination of elbasvir-grazoprevir, with or without ribavirin, in treatment-naïve HCV-monoinfected (part A) or HCV-HIV coinfected (part B) patients without cirrhosis  Entry Criteria - Chronic HCV genotype 1 - Age 18 years or older - HCV RNA ≥10,000 IU/mL - No prior treatment - No cirrhosis - Part B: well- controlled HIV infection (on antiretroviral therapy ≥8 weeks, HIV RNA undetectable x ≥24 weeks and CD4 count ≥300 cells/mm 3  Primary End-Point : SVR12 Source: Sulkowski M, et al. Lancet. 2015;385:1087-97.

  65. Elbasvir + Grazoprevir +/- RBV in HCV GT1 +/- HIV Coinfection C-WORTHY Coinfection: Study: Study Design Part A Week 0 12 24 n = 25 GT 1a + 1b A1 EBR (20 mg) + GZR + RBV SVR12 Group A Treatment-Naive n = 27 GT 1a + 1b A2 EBR (50 mg) + GZR + RBV SVR12 HCV Monoinfected SVR12 n = 13 GT 1b A3 EBR (50 mg) + GZR Abbreviations : EBR = elbasvir; GZR = grazoprevir; RBV = ribavirin Drug Dosing Elbasvir (20 mg or 50 mg) once daily Grazoprevir (100 mg) once daily Ribavirin (weight-based and divided bid): 800 to 1400 mg/day Source: Sulkowski M, et al. Lancet. 2015;385:1087-97.

  66. Elbasvir+ Grazoprevir +/- RBV in HCV GT1 +/- HIV Coinfection C-WORTHY Coinfection: Study: Study Design Part B Week 0 8 12 20 24 n = 30 GT 1a B1 EBR + GZR (50 mg) + RBV SVR12 Group B Treatment-Naive GT 1a + 1b B2 n = 33 EBR + GZR (50 mg) + RBV SVR12 HCV Monoinfected SVR12 GT 1a B3 EBR + GZR (50 mg) n = 31 Group B GT 1a + 1b B12 n = 29 EBR + GZR SVR12 Treatment-Naive SVR12 HIV Coinfected GT 1a + 1b B13 EBR + GZR n = 30 Abbreviations : EBR = elbasvir; GZR = grazoprevir; RBV = ribavirin Drug Dosing Elbasvir (50 mg) once daily Grazoprevir (100 mg) once daily Ribavirin (weight-based and divided bid): 800 to 1400 mg/day Source: Sulkowski M, et al. Lancet. 2015;385:1087-97.

  67. Elbasvir + Grazoprevir +/- RBV in HCV GT1 +/- HIV Coinfection C-WORTHY Coinfection: Results C-WORTHY: SVR12 Results by Treatment and HIV Coinfection Status 100 98 97 Patients with SVR12 (%) 93 87 80 80 60 40 20 24/30 79/85 43/44 28/29 26/30 0 8 weeks 12 weeks 12 weeks 12 weeks 12 weeks (+ Ribavirin) (+ Ribavirin) (- Ribavirin) (+ Ribavirin) (- Ribavirin) Arm B1 Arms A1, A2, B2 Arms A3, B3 Arm B12 Arm B13 HCV Monoinfected HCV-HIV Coinfected Source: Sulkowski M, et al. Lancet. 2015;385:1087-97.

  68. Elbasvir + Grazoprevir +/- RBV in HCV GT1 +/- HIV Coinfection C-WORTHY Coinfection: Study: Results C-WORTHY: SVR12 Rates by HCV GT1 Subtype and Use of Ribavirin Elbasvir + Grazoprevir + Ribavirin Elbasvir + Grazoprevir 100 95 Patients (%) with SVR 12 95 92 92 80 60 40 20 72/76 48/52 33/36 21/22 0 Genotype 1a Genotype 1b Source: Sulkowski M, et al. Lancet. 2015;385:1087-97.

  69. Elbasvir + Grazoprevir +/- RBV in HCV GT1 +/- HIV Coinfection C-WORTHY Coinfection: Study Features Interpretation : “ Once-daily grazoprevir plus elbasvir with or without ribavirin for 12 weeks in previously untreated HCV-mono-infected and HIV/HCV-co-infected patients without cirrhosis achieved SVR12 rates of 87-98%. These results support the ongoing phase 3 development of grazoprevir plus elbasvir. ” Source: Sulkowski M, et al. Lancet. 2015;385:1087-97.

  70. Elbasvir-Grazoprevir in Patients with Renal Disease

  71. Phase 3 Treatment Naïve and Treatment Experienced Elbasvir + Grazoprevir in GT 1 and Chronic Renal Disease C-SURFER Source: Roth D, et al. Lancet 2015;386:1537-45.

  72. Elbasvir + Grazoprevir in HCV GT1 and Renal Disease C-SURFER Study: Features C-SURFER  Design : Randomized, phase 3, double-blind trial examining the safety and efficacy of elbasvir plus grazoprevir for 12 weeks in treatment-naïve or treatment-experienced patients genotype 1 chronic HCV and stage 4 or 5 chronic renal disease, including patients on hemodialysis.  Setting : 68 international sites  Entry Criteria - Chronic HCV genotype 1 - Chronic kidney disease (Stage 4 or 5) +/- hemodialysis - Age 18 years or older - Treatment naïve or treatment-experienced - Cirrhosis allowed  Primary End-Point : SVR12 Source: Roth D, et al. Lancet 2015;386:1537-45.

  73. Elbasvir + Grazoprevir in HCV GT1 and Renal Disease C-SURFER Study: Study Design Week 0 12 16 40 24 28 Immediate Treatment N=111 SVR12 EBZ + GRZ TN TE Deferred Therapy Deferred Therapy SVR12 N=113 EBZ + GRZ Placebo GT 1 Stage 4 or 5 CKD Intensive PK SVR12 N=11 EBZ + GRZ Drug Dosing Grazoprevir 100 mg once daily and Elbasvir 50 mg once daily; given as separate medications in Immediate treatment and Intensive PK arms; given as fixed dose combination in Deferred arm Source: Roth D, et al. Lancet 2015;386:1537-45.

  74. Elbasvir + Grazoprevir in HCV GT1 and Renal Disease C-SURFER Study: Participants EBR + GZR EBR + GZR EBR + GZR Baseline Total Immediate Deferred PK (n =235) Characteristic (n =111) (n =113) (n =11) Mean age, years (SD) 56.5 (9.1) 55.2 (10.1) 58.2 (6.8) 56 (9.5) Male sex, % 73 71 100 73 Race, % White 50 43 54 47 Black 45 47 45 46 Asian 5 8 0 6 HCV Genotype, % 1a 48 52 91 52 1b 52 47 9 48 1 other 0 1 0 0 Cirrhosis, % 6 6 0 6 Treatment-naïve, % 82 78 91 80 Diabetes, % 34 32 55 34 Kidney disease severity Stage 4, % 16 20 36 19 Stage 5, % 84 80 64 81 On dialysis, % 78 77 55 76 Source: Roth D, et al. Lancet 2015;386:1537-45.

  75. Elbasvir + Grazoprevir in HCV GT1 and Renal Disease C-SURFER Study: Results C-SURFER: SVR12 Results 100 99 94 80 SVR12 (%) 60 40 20 115/116 115/122 0 Modifed Full Analysis Set Full Analysis Set Modified analysis excluded patients who did not receive ≥1 dose of drug or who died or discontinued early for reasons unrelated to HCV treatment. Source: Roth D, et al. Lancet 2015;386:1537-45.

  76. Elbasvir + Grazoprevir in HCV GT1 and Renal Disease C-SURFER Study: Safety Elbasvir + Grazoprevir Adverse Event (AE), n (%) Immediate Deferred (Placebo) (n = 111) (n = 113) Discontinuation due to AE 0 5 (4.4) Serious AEs 16 (14.4) 19 (16.8) Deaths 1 (0.8) 3 (2.7) Any AE in ≥10% of patients 84 (75.7) 95 (84.1) Headache 19 (17.1) 19 (16.8) Nausea 17 (15.3) 18 (15.9) Fatigue 11 (9.9) 17 (15.9) Insomnia 7 (6.3) 12 (10.6) Dizziness 6 (5.4) 18 (15.9) Diarrhea 6 (5.4) 15 (13.3) Laboratory AEs Hemoglobin <8.5 g/dl 5 (4.5) 5 (4.4) ALT 1.1-2.5 x baseline 2 (1.8) 36 (31.9) Creatinine § >2.5 x baseline 1 (1.2) 0 § Among patients not on dialysis at baseline. Source: Roth D, et al. Lancet 2015;386:1537-45.

  77. Elbasvir + Grazoprevir in HCV GT1 and Renal Disease C-SURFER Study: Conclusions Interpretation : “ Once-daily grazoprevir and elbasvir for 12 weeks had a low rate of adverse events and was effective in patients infected with HCV genotype 1 and stage 4-5 chronic kidney disease. ” Source: Roth D, et al. Lancet 2015;386:1537-45.

  78. Phase 2/3 Treatment Naïve and Treatment Experienced Elbasvir-Grazoprevir +/- Ribavirin in HCV GT 4 Pooled Analysis Source: Asselah T, et al. Liver Int. 2018;38:1583-91.

  79. Elbasvir-Grazoprevir +/- RBV in HCV GT4 Pooled Analysis: Study Features C-EDGE Trial  Design : Pooled analysis of treatment naïve and treatment experienced adults with HCV genotype 4 who participated in phase 2 and 3 clinical trials involving treatment with elbasvir-grazoprevir for 12-16 weeks, with or without ribavirin.  Entry Criteria - Chronic HCV genotype 4 (n = 155) - 18 years or older - Baseline HCV RNA ≥10,000 IU/mL - Treatment naïve & Treatment experienced (prior PEG-INF-based failure) - Persons with compensated cirrhosis permitted - Persons with HIV infection permitted  Primary End-Point : SVR12 Source: Asselah T, et al. Liver Int. 2018;38:1583-91.

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend

C-SCAPE Source: Brown A, et al. J Viral Hepat. 2018;25:457-64. Elbasvir + Grazoprevir +/- RBV in

C-SCAPE Source: Brown A, et al. J Viral Hepat. 2018;25:457-64. Elbasvir + Grazoprevir +/- RBV in

Phase 2 Treatment Nave Elbasvir + Grazoprevir +/- Ribavirin in Treatment-Nave HCV GT 2, 4, 5, or 6 C-SCAPE Source: Brown A, et al. J Viral Hepat. 2018;25:457-64. Elbasvir + Grazoprevir +/- RBV in Treatment-Nave GT 2, 4, 5 or 6 C-SCAPE

322 views • 6 slides
C-EDGE Treatment Experienced (TE) Source: Kwo P, et al. Gastroenterology. 2017;152:164-75.

C-EDGE Treatment Experienced (TE) Source: Kwo P, et al. Gastroenterology. 2017;152:164-75.

Phase 3 Treatment Experienced Elbasvir-Grazoprevir +/- Ribavirin in HCV Genotype 1, 4 or 6 C-EDGE Treatment Experienced (TE) Source: Kwo P, et al. Gastroenterology. 2017;152:164-75. Elbasvir-Grazoprevir +/- Ribavirin in HCV Genotype 1, 4 or 6

585 views • 9 slides
Merck Announces Presentation of Phase 2 Clinical Trial Results of Investigational Chronic

Merck Announces Presentation of Phase 2 Clinical Trial Results of Investigational Chronic

NEWS RELEASE Merck Announces Presentation of Phase 2 Clinical Trial Results of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir at the International Liver CongressTM 2015 4/25/2015 Results of C-SALVAGE Study Showed High

97 views • 5 slides
Precise Parameter Synthesis for Stochastic Biochemical Systems Milan ska 1 , 2 , Frits

Precise Parameter Synthesis for Stochastic Biochemical Systems Milan ska 1 , 2 , Frits

Introduction Problem Formulation Parameter Synthesis Case Studies Conclusion Precise Parameter Synthesis for Stochastic Biochemical Systems Milan ska 1 , 2 , Frits Dannenberg 2 , Marta Kwiatkowska 2 , Nicola Paoletti 2 Ce Faculty of

579 views • 28 slides
5/23/2015 Small Glandular Proliferative Complex sclerosing lesion Benign lobules in fat

5/23/2015 Small Glandular Proliferative Complex sclerosing lesion Benign lobules in fat

5/23/2015 Small Glandular Proliferative Complex sclerosing lesion Benign lobules in fat Microglandular adenosis Lesions of the Breast Sclerosing adenosis Tubular carcinoma Small Glandular Yunn-Yi Chen, MD, PhD Lesions of Breast Professor

449 views • 28 slides
University of Genoa Academic year 2020 Joel Guerrero joel.guerrero@unige.it Photo by Ava W.

University of Genoa Academic year 2020 Joel Guerrero joel.guerrero@unige.it Photo by Ava W.

University of Genoa Academic year 2020 Joel Guerrero joel.guerrero@unige.it Photo by Ava W. on Unsplash Our world is continuous But the world of numerical simulations is discrete Let us take a closer look to this pixelated area. In

368 views • 15 slides
On the global convergence of a singularly perturbed parabolic problem of reaction diffusion type

On the global convergence of a singularly perturbed parabolic problem of reaction diffusion type

Outline Fitted mesh Fitted operator Regularized Problem Fitted operator and fitted mesh On the global convergence of a singularly perturbed parabolic problem of reaction diffusion type with a discontinuous initial condition J.L. Gracia, E.

973 views • 37 slides
Mapping Text to Meaning Learning to Map Sentences to Logical Form Natural Meaning Language M

Mapping Text to Meaning Learning to Map Sentences to Logical Form Natural Meaning Language M

Mapping Text to Meaning Learning to Map Sentences to Logical Form Natural Meaning Language M Representation ( NL ) ( MR ) Input: (text strings) Luke Zettlemoyer Natural language text Output: (formal meaning representation) A

602 views • 16 slides
AMC Worcester Chapter November 5, 2014 Presented by: Mike Jones, Debi Garlick, Pat Lambert,

AMC Worcester Chapter November 5, 2014 Presented by: Mike Jones, Debi Garlick, Pat Lambert,

AMC Worcester Chapter November 5, 2014 Presented by: Mike Jones, Debi Garlick, Pat Lambert, Paul Glazebrook, Charlie Arsenault, Joe Massery, Liz Brown Introductions: Charlie Purpose of the Workshop/Hike Series: Charlie Purpose of

508 views • 48 slides
Computational Logic Introduction to Logic Programming 1 Overview 1. Syntax: data 2.

Computational Logic Introduction to Logic Programming 1 Overview 1. Syntax: data 2.

Computational Logic Introduction to Logic Programming 1 Overview 1. Syntax: data 2. Manipulating data: unification 3. Syntax: code 4. Semantics: meaning of programs 5. Executing logic programs 2 Syntax: Terms (Variables, Constants, and

545 views • 42 slides
Normalization: Friend or Foe Beth Tucker Long Who am I? Beth Tucker Long (@e3betht) Editor

Normalization: Friend or Foe Beth Tucker Long Who am I? Beth Tucker Long (@e3betht) Editor

Normalization: Friend or Foe Beth Tucker Long Who am I? Beth Tucker Long (@e3betht) Editor in Chief php[architect] magazine Freelancer under Treeline Design, LLC Stay at home mom User group organizer

880 views • 38 slides
Aggregate Message Authentication Codes with Detecting Functionality from Biorthogonal Codes

Aggregate Message Authentication Codes with Detecting Functionality from Biorthogonal Codes

IEEE IS IE ISIT IT 20 2020 Aggregate Message Authentication Codes with Detecting Functionality from Biorthogonal Codes Yoshinori Ogawa *, Shingo Sato** Junji Shikata*, Hideki Imai*** *Yokohama National University, Japan **NICT, Japan

254 views • 13 slides
Runtime support for region-based memory management in Mercury Quan Phan*, Zoltan Somogyi**,

Runtime support for region-based memory management in Mercury Quan Phan*, Zoltan Somogyi**,

Runtime support for region-based memory management in Mercury Quan Phan*, Zoltan Somogyi**, Gerda Janssens* * DTAI, KU Leuven, Belgium. ** Computer Science and Software Engineering Department, University of Melbourne, Australia. ISMM 2008

364 views • 25 slides
Formalising Algorithmic Correspondence for Modal Languages Removing propositional variables with

Formalising Algorithmic Correspondence for Modal Languages Removing propositional variables with

Formalising Algorithmic Correspondence for Modal Languages Removing propositional variables with SQEMA in Coq by Merlin Gttlinger February 20, 2018 Fundamentals 2/52 Fundamentals Modal Syntax Fundamentals 3/52 Let All sets

808 views • 52 slides
Implying or implicating not both in declaratives and interrogatives Matthijs Westera

Implying or implicating not both in declaratives and interrogatives Matthijs Westera

Implying or implicating not both in declaratives and interrogatives Matthijs Westera Universitat Pompeu Fabra Aim Aim (1) John was at the party, or Mary. (L%) Aim (1) John was at the party, or Mary. (L%) (2) Was John at

1.21k views • 90 slides
CS156: The Calculus of Given Theories T i over signatures i Computation with corresponding

CS156: The Calculus of Given Theories T i over signatures i Computation with corresponding

Combining Decision Procedures: Nelson-Oppen Method CS156: The Calculus of Given Theories T i over signatures i Computation with corresponding decision procedures P i for T i -satisfiability. Zohar Manna Goal Winter 2010 Decide

637 views • 8 slides
Perturbation theory of computing QCD jet cross sections beyond NLO accuracy Zoltn Trcsnyi

Perturbation theory of computing QCD jet cross sections beyond NLO accuracy Zoltn Trcsnyi

Introduction pQCD computation of jet cross sections Extension to NNLO NLO subtraction revisited Summary Extra slides Perturbation theory of computing QCD jet cross sections beyond NLO accuracy Zoltn Trcsnyi University of Debrecen and

1.11k views • 76 slides
gMark: Schema-Driven Generation of Graphs and Queries Radu Ciucanu Universit e Clermont

gMark: Schema-Driven Generation of Graphs and Queries Radu Ciucanu Universit e Clermont

gMark: Schema-Driven Generation of Graphs and Queries Radu Ciucanu Universit e Clermont Auvergne Joint work with colleagues from Univ. Lille, Univ. Lyon, TU Eindhoven JIRC 2017, Orl eans Radu Ciucanu gMark: Schema-Driven Generation of

679 views • 41 slides
Implementing Critical Sections in Software Hard The following example

Implementing Critical Sections in Software Hard The following example

Implementing Critical Sections in Software Hard The following example will demonstrate the difficulty of providing mutual exclusion with memory reads and writes Hardware support is needed The code must work all of

228 views • 3 slides
A Comparison of Knives for Bread Slicing Alekh Jindal*, Endre Palatinus, Vladimir Pavlov, Jens

A Comparison of Knives for Bread Slicing Alekh Jindal*, Endre Palatinus, Vladimir Pavlov, Jens

A Comparison of Knives for Bread Slicing Alekh Jindal*, Endre Palatinus, Vladimir Pavlov, Jens Dittrich Information Systems Group Saarland University *MIT CSAIL Data Layout 2 Row-layout CUSTKEY NATIONKEY NAME MKTSEGMENT ADDRESS COMMENT

418 views • 39 slides
Notes Simplifications of Elasticity Today 4pm, Dempster 310 Demetri Terzopoulos is talking

Notes Simplifications of Elasticity Today 4pm, Dempster 310 Demetri Terzopoulos is talking

Notes Simplifications of Elasticity Today 4pm, Dempster 310 Demetri Terzopoulos is talking Please read Pentland and Williams, Good vibrations, SIGGRAPH 89 cs533d-term1-2005 1 cs533d-term1-2005 2 Rotated Linear Elements

464 views • 7 slides
Clark-Wilson Integrity Model Integrity defined by a set of constraints Data in a

Clark-Wilson Integrity Model Integrity defined by a set of constraints Data in a

Clark-Wilson Integrity Model Integrity defined by a set of constraints Data in a consistent or valid state when it satisfies these Example: Bank D todays deposits, W withdrawals, YB yesterdays balance, TB todays balance

1.06k views • 59 slides
Earthquake Vulnerability Earthquake Vulnerability Vulnerability Assessment &amp; EVR measures

Earthquake Vulnerability Earthquake Vulnerability Vulnerability Assessment &amp; EVR measures

Earthquake Vulnerability Earthquake Vulnerability Vulnerability Assessment &amp; EVR measures Islamabad Pakistan Assessment and Vulnerability Assessment and Vulnerability Reduction Measures Reduction Measures adpc Asian Disaster

702 views • 46 slides
Aera%on tank loading and dimensioning CTB3365x Introduc1on to

Aera%on tank loading and dimensioning CTB3365x Introduc1on to

Aera%on tank loading and dimensioning CTB3365x Introduc1on to water treatment Dr.ir. Merle de Kreuk Aera%on tank loading and dimensioning Aera%on tank

381 views • 18 slides

More recommend